The Interplay Between Bone and Heart Health As Reflected in Medication Effects: A Narrative Review

Overview

Journal Womens Health (Lond)

Specialty Gynecology & Obstetrics

Date 2023 Apr 20

PMID 37078403

Authors

Susanne Trost

Nolawit Tesfaye

Tasma Harindhanavudhi

Affiliations

Soon will be listed here.

Abstract

There is mounting evidence of an association between osteoporosis and cardiovascular disease that extends beyond shared risk factors for these conditions. In turn, the medications used to treat each of these conditions can have effects that impact the other organ system: medications used in heart disease have the potential to affect bone health, while osteoporosis medications may modify cardiovascular health. While data in this subject area are limited by the paucity of large randomized controlled trials with bone mineral density or fracture risk as primary outcomes, this review explores the data available that can provide some insight into these reciprocal effects of medications on bone and heart health. Data on bone health effects of the loop and thiazide diuretics, beta blockers, calcium channel blockers, statins, warfarin, sodium-glucose cotransporter 2 inhibitors, metformin, and medications impacting the renin-angiotensin-aldosterone system are examined; the cardiovascular effects of osteoporosis therapies and vitamin D are also discussed. Importantly, while most data in this realm are inconclusive, recognizing the parallels between cardiovascular and bone disorders and how this is reflected in medication effects might prompt the clinician to consider the indirect impact of drug regimens when making therapeutic choices for patients with osteoporosis and heart disease.

Citing Articles

Ten-year atherosclerotic cardiovascular disease risk score in post-menopausal women with low bone mineral density.

Wani K, Sabico S, Veronese N, Al-Masri A, Al-Daghri N Aging Clin Exp Res. 2025; 37(1):56.

PMID: 40011291 PMC: 11865107. DOI: 10.1007/s40520-025-02957-1.

Heart Failure and Osteoporosis: Shared Challenges in the Aging Population.

Spoladore R, Ciampi C, Ossola P, Sultana A, Spreafico L, Farina A J Cardiovasc Dev Dis. 2025; 12(2).

PMID: 39997503 PMC: 11856909. DOI: 10.3390/jcdd12020069.

Effects of Selective and Nonselective Beta Blockers on Bone Mineral Density in Mexican Patients with Breast Cancer.

Mejia-Barradas C, Amador-Martinez A, Lara-Padilla E, Cardenas-Rodriguez N, Ignacio-Mejia I, Martinez-Lopez V Cancers (Basel). 2024; 16(16).

PMID: 39199661 PMC: 11352457. DOI: 10.3390/cancers16162891.

Femoral Neck Osteoporosis Is Associated with a Higher Odds of Coronary Artery Disease in Indian Postmenopausal Women: A Cross-sectional Study from a Teaching Hospital in Southern India.

Binu A, Mittal A, Cherian K, Ravi L, Agarwal M, Alex A Heart Int. 2024; 18(1):51-55.

PMID: 39006463 PMC: 11239136. DOI: 10.17925/HI.2024.18.1.8.

Vitamin D and cardiovascular diseases: A narrative review.

Alissa E J Family Med Prim Care. 2024; 13(4):1191-1199.

PMID: 38827691 PMC: 11141959. DOI: 10.4103/jfmpc.jfmpc_1481_23.

References

Kelishadi R, Farajzadegan Z, Bahreynian M . Association between vitamin D status and lipid profile in children and adolescents: a systematic review and meta-analysis. Int J Food Sci Nutr. 2014; 65(4):404-10. DOI: 10.3109/09637486.2014.886186. View

Chan K, Andrade S, Boles M, Buist D, Chase G, Donahue J . Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet. 2000; 355(9222):2185-8. DOI: 10.1016/S0140-6736(00)02400-4. View

Szekanecz Z, Raterman H, Petho Z, Lems W . Common mechanisms and holistic care in atherosclerosis and osteoporosis. Arthritis Res Ther. 2019; 21(1):15. PMC: 6329187. DOI: 10.1186/s13075-018-1805-7. View

Sing C, Wong A, Kiel D, Cheung E, Lam J, Cheung T . Association of Alendronate and Risk of Cardiovascular Events in Patients With Hip Fracture. J Bone Miner Res. 2018; 33(8):1422-1434. DOI: 10.1002/jbmr.3448. View

Scranton R, Young M, Lawler E, Solomon D, Gagnon D, Gaziano J . Statin use and fracture risk: study of a US veterans population. Arch Intern Med. 2005; 165(17):2007-12. DOI: 10.1001/archinte.165.17.2007. View

Cheng L, Li Y, Hu W, Bai F, Hao H, Yu W . Risk of bone fracture associated with sodium-glucose cotransporter-2 inhibitor treatment: A meta-analysis of randomized controlled trials. Diabetes Metab. 2019; 45(5):436-445. DOI: 10.1016/j.diabet.2019.01.010. View

Ferrieres L, Degboe Y, Laroche M, Constantin A, Ruyssen-Witrand A . No impact of anti-Rank ligand and PTH analogs on cardiovascular risk in postmenopausal osteoporosis: a systematic literature review and meta-analysis. Arch Osteoporos. 2020; 15(1):10. DOI: 10.1007/s11657-019-0672-4. View

Grammatiki M, Karras S, Kotsa K . The role of vitamin D in the pathogenesis and treatment of diabetes mellitus: a narrative review. Hormones (Athens). 2018; 18(1):37-48. DOI: 10.1007/s42000-018-0063-z. View

Cheng K, Liao K, Lin C, Lin C, Lai S . Case-control study examining the association between hip fracture risk and statins therapy in old people. Medicine (Baltimore). 2019; 98(41):e17476. PMC: 6799492. DOI: 10.1097/MD.0000000000017476. View

10.

Sirola J, Honkanen R, Kroger H, Jurvelin J, Maenpaa P, Saarikoski S . Relation of statin use and bone loss: a prospective population-based cohort study in early postmenopausal women. Osteoporos Int. 2002; 13(7):537-41. DOI: 10.1007/s001980200070. View

11.

Rejnmark L, Vestergaard P, Mosekilde L . Fracture risk in users of oral anticoagulants: a nationwide case-control study. Int J Cardiol. 2006; 118(3):338-44. DOI: 10.1016/j.ijcard.2006.07.022. View

12.

Bergman J, Nordstrom A, Hommel A, Kivipelto M, Nordstrom P . Bisphosphonates and mortality: confounding in observational studies?. Osteoporos Int. 2019; 30(10):1973-1982. PMC: 6795608. DOI: 10.1007/s00198-019-05097-1. View

13.

Prezelj J, Kocijancic A . Antiandrogen treatment with spironolactone and linestrenol decreases bone mineral density in eumenorrhoeic women with androgen excess. Horm Metab Res. 1994; 26(1):46-8. View

14.

Woo C, Chang L, Ewing S, Bauer D . Single-point assessment of warfarin use and risk of osteoporosis in elderly men. J Am Geriatr Soc. 2008; 56(7):1171-6. PMC: 2753381. DOI: 10.1111/j.1532-5415.2008.01786.x. View

15.

Wu Z, Wang T, Zhu S, Li L . Effects of vitamin D supplementation as an adjuvant therapy in coronary artery disease patients. Scand Cardiovasc J. 2015; 50(1):9-16. DOI: 10.3109/14017431.2015.1103893. View

16.

Kwok T, Leung J, Zhang Y, Bauer D, Ensrud K, Barrett-Connor E . Does the use of ACE inhibitors or angiotensin receptor blockers affect bone loss in older men?. Osteoporos Int. 2011; 23(8):2159-67. PMC: 3772278. DOI: 10.1007/s00198-011-1831-7. View

17.

Reid I, Horne A, Mihov B, Stewart A, Garratt E, Bastin S . Effects of Zoledronate on Cancer, Cardiac Events, and Mortality in Osteopenic Older Women. J Bone Miner Res. 2019; 35(1):20-27. DOI: 10.1002/jbmr.3860. View

18.

Scragg R, Jackson R, Holdaway I, Lim T, Beaglehole R . Myocardial infarction is inversely associated with plasma 25-hydroxyvitamin D3 levels: a community-based study. Int J Epidemiol. 1990; 19(3):559-63. DOI: 10.1093/ije/19.3.559. View

19.

Pilz S, Trummer C, Theiler-Schwetz V, Grubler M, Verheyen N, Odler B . Critical Appraisal of Large Vitamin D Randomized Controlled Trials. Nutrients. 2022; 14(2). PMC: 8778517. DOI: 10.3390/nu14020303. View

20.

Jorde R, Grimnes G . Vitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids. Prog Lipid Res. 2011; 50(4):303-12. DOI: 10.1016/j.plipres.2011.05.001. View